HPGDS-IN-1

HPGDS-IN-1 (Compound 2[3]) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA) . hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons[1][2][3].

Product Specifications

CAS Number

[1234708-04-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PGE synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hPGDS-IN-1.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC(C)(C)C1=NC(C2=CC(CNC(C(C=N3)=CN=C3C4=CC=CC=N4)=O)=CC=C2)=NO1

Molecular Formula

C22H20N6O3

Molecular Weight

416.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.|[2]Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.|[3]Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16 (12), 1967-1969.|[4]González-Llera L, et al. An in vivo drug screen in zebrafish reveals that cyclooxygenase 2-derived prostaglandin D2 promotes spinal cord neurogenesis. Cell Prolif. 2024 May;57 (5) :e13594.